Business Context and Reporting Period
This Form 8-K Current Report was filed by Cocrystal Pharma, Inc. on July 21, 2015. The filing reports the appointment of a new principal officer and the associated compensatory arrangements.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to executive compensation:
- Annual Base Salary: $225,000
- Discretionary Bonus: Up to 35% of annual base salary
- Stock Options: 1,200,000 ten-year options vesting in four equal annual increments
Material Changes
On July 21, 2015, the Board of Directors appointed Walt Linscott, Esq. as General Counsel and Corporate Secretary, effective July 15, 2015. This represents a change in the Company's principal officers.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, or management commentary regarding business operations. No specific risks or contingencies are disclosed in this report, other than the standard vesting conditions for the stock options granted.
Investor Verification Checklist
- Verify the terms of the Employment Agreement (Exhibit 10.1) and Stock Option Agreement (Exhibit 10.2) filed with this report.
- Confirm the vesting schedule and acceleration conditions for the 1,200,000 stock options granted to Mr. Linscott.
- Review the Company's most recent 10-K or 10-Q for current financial position, as this 8-K does not contain financial statements.